BPC-157 Side Effects and Safety

Safety & Tolerability

Across preclinical research, BPC-157 has been reported to have a favorable tolerability profile: a 2021 Frontiers in Pharmacology review noted no reported toxicity in animal studies, with the LD1 (lethal dose for 1% of animals) not reached. All quantitative safety findings derive from animal and in-vitro models; controlled human safety data is limited and incomplete. Human data: Human exposure is limited and largely unpublished. BPC-157 (as PL-14736) was evaluated in early human inflammatory-bowel-disease/ulcerative-colitis trials and reportedly in multiple-sclerosis trials; these were not completed in peer-reviewed form, and a Phase I safety study has been mentioned in the literature but its results were never published. No completed, peer-reviewed human efficacy or long-term safety trial exists as of 2026. Regulatory status: Not approved by the FDA (or any regulatory agency) for human use. Prohibited in sport under the WADA Prohibited List, category S0 (Non-Approved Substances). A 2021 review reported no toxicity in BPC-157 animal studies, with the LD1 not achieved, and noted prior use in ulcerative colitis and multiple sclerosis trials. Animal A 2021 review reported no toxicity in BPC-157 animal studies, with the LD1 not achieved, and noted prior use in ulcerative colitis and multiple sclerosis trials. Early human IBD/ulcerative-colitis trials of BPC-157 (PL-14736) reported it as safe with no reported toxicity — but these clinical trials were not completed or fully published. Human trial Early human IBD/ulcerative-colitis trials of BPC-157 (PL-14736) reported it as safe with no reported toxicity — but these clinical trials were not completed or fully published. BPC-157 was formally evaluated "in trials for inflammatory bowel disease" (PL-10, PLD-116, PL-14736; Pliva, Croatia), documenting an early human development program that was not carried to completion. Human trial BPC-157 was formally evaluated "in trials for inflammatory bowel disease" (PL-10, PLD-116, PL-14736; Pliva, Croatia), documenting an early human development program that was not carried to completion.